Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...

HOUSTON, Dec. 3, 2025 /PRNewswire/ -- Avance Biosciences today announced the opening of its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and ...

A naturally occurring mutation in T cells that leads to lymphoma can be weaponized to make engineered T-cell therapies more effective against cancer, including melanoma, findings from a new study in ...

Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived ...

While the use of cell therapies to treat hematological malignancies has been hailed as a clinical breakthrough, this promising new class of therapies has been far less effective in treating solid ...

MIAMI - Longeveron Inc. (NASDAQ:LGVN) announced Thursday that the Japan Patent Office has granted a patent covering potency assay methods for assessing human mesenchymal stem cells (MSCs). The ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...